Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
November 14 2012 - 9:59AM
Edgar (US Regulatory)
Filed Pursuant to Rule 433
Issuer Free Writing Prospectus dated November 14, 2012
Supplementing the Preliminary Prospectus Supplement
dated November 13, 2012
Relating to Registration Statement No.
333-181277
Common Stock
This free writing prospectus relates only to the securities described
in, and should be read together with, the preliminary prospectus supplement dated November 13, 2012 (the “Preliminary Prospectus
Supplement”). The following information supplements and updates the
information contained in the Preliminary Prospectus Supplement:
Issuer:
|
MAKO Surgical Corp. (the “Company”)
|
Symbol / Exchange for common stock:
|
MAKO
/ NASDAQ Global Select Market (“NASDAQ”)
|
Security:
|
Common stock, par value $ 0.001 per share
|
Size:
|
3,042,000
shares of common stock
|
Over-allotment option:
|
456,300
additional shares of common stock
|
Public offering price:
|
$13.15
per share
|
NASDAQ closing price on November 13, 2012:
|
$13.21
|
Underwriting discounts and commissions:
|
$0.789
per share
|
Net proceeds (excluding the over-allotment):
|
$37.1
million (after deducting the underwriter’s discounts and commissions and estimated offering expenses payable by the Company)
|
Dilution per share to new investors in this offering:
|
$10.44
per share
|
Trade date:
|
November 14, 2012
|
Settlement date:
|
November 19, 2012
|
Underwriter:
|
Piper Jaffray & Co.
|
Financial Advisor:
|
Moelis
& Company acted as a financial advisor to the Company with respect to certain matters in connection with the
offering. Its fees will be paid by the underwriter.
|
Pipeline Biomedical Holdings, Inc.:
|
On
November 13, 2012, we issued 490,471
shares of common stock to Pipeline Biomedical Holdings, Inc. and we registered
those shares for resale on a shelf registration statement on November 14, 2012.
|
The Company has filed a
registration statement (including a base prospectus and a preliminary prospectus supplement thereto) with the Securities
and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you
should read the base prospectus and the preliminary prospectus supplement in that registration statement and other documents
the Company has filed with the SEC for more complete information about the Company and this offering. You may get these
documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, a base prospectus and accompanying
preliminary prospectus supplement may be obtained from Piper Jaffray & Co. at 800 Nicollet Mall, Minneapolis, MN 55402,
Attention: Equity Capital Markets, or by telephone at (800) 747-3924.
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024